| Globe & Mail (Toronto, Canada) 2004 Leonard Zehr |
| Title | Subject | Authors |
|---|
| Biovail faces possible FDA hitch to pain drug. | News, opinion and commentary | Leonard Zehr |
| Biovail trading raises red flags: OSC notes pattern of dramatic selloffs ahead of corporate news releases.(Ontario Securities Commission) | News, opinion and commentary | Karen Howlett, Leonard Zehr |
| Bird flu challenges the world's vaccine makers. | News, opinion and commentary | Leonard Zehr |
| Cyber drugstores feel the heat from US. | News, opinion and commentary | Leonard Zehr |
| Inex (again) sees drug plans turn to 'zero value'. | News, opinion and commentary | Leonard Zehr |
| Laser vision surgery staging comeback. | News, opinion and commentary | Leonard Zehr |
| Merck hammered after massive drug recall: Decision to pull Vioxx termed 'a disaster'.(Merck and Company Inc.) | News, opinion and commentary | Leonard Zehr |
| New Lorus drug shows promising results: Company enters final leg of clinical study for pancreatic cancer treatment Virulizin. | News, opinion and commentary | Leonard Zehr |
| Patheon buying rival Puerto Rican drug maker. | News, opinion and commentary | Leonard Zehr |
| Transition therapeutics confident of deal with Novo on diabetes treatment.(Nova Nordisk AS ) | News, opinion and commentary | Leonard Zehr |
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
